Bristol-Myers Squibb, schizophrenia

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the latter part of the year.
Bristol-Myers Squibb Co (BMY) Stock’s -0.01% Decrease This Year: What’s the Story?
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and touched a low of $55.
Bristol Myers Squibb CEO describes new drug for treating schizophrenia
Bristol Myers Squibb CEO Chris Boerner described Cobenefy, a new drug to treat schizophrenia and may also help with bipolar disorder and Alzheimer’s disease.
Feedback on schizophrenia treatment has been great, says Bristol Myers Squibb CEO
Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk its new schizophrenia treatment Cobenfy, its oncology business, and more.
Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports
Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older
Bristol Myers Says New Schizophrenia Drug Off to Strong Start
Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of Karuna Therapeutics is paying off.
bovnews18h
Bristol-Myers Squibb Co (BMY) Stock Posted a Gross Margin of 55.87% Over the Past Year: Is This Justifiable?
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...
Wedmont Private Capital Has $586,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)
Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th ...
Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
The stock's rise snapped a three-day losing streak.
Bristol-Myers Squibb (NYSE:BMY) Position Increased by Legacy Private Trust Co.
Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...
ArsenalBios Says Bristol Myers Squibb Exercises Exclusive License Option For AB-4000 Series Programs
Arsenal Biosciences, Inc., a clinical-stage programmable cell therapy company, announced Monday that drug maker Bristol-Myers Squibb ...
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
This was the stock's third consecutive day of losses.
CSR Wire4d
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year
Bristol Myers Squibb announced that it has been named in the prestigious Dow Jones Sustainability Index (DJSI) for the second ...